NASDAQ:XOMA - XOMA Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.03 -1.02 (-4.07 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$25.05
Today's Range$23.90 - $25.18
52-Week Range$6.86 - $37.25
Volume65,000 shs
Average Volume118,719 shs
Market Capitalization$209.90 million
P/E Ratio15.95
Dividend YieldN/A
Beta2.91
XOMA logoXOMA Corporation engages in the discovery, development, and licensing of therapeutic antibodies in the United States, Europe, and the Asia Pacific. The company has a portfolio of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and other preclinical product candidates, such as interleukin 2, a therapy for metastatic melanoma and renal cell carcinoma, as well as anti-parathyroid receptor to address unmet medical needs. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration and licensing agreements with Novartis AG; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Emeryville, California.

Receive XOMA News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:XOMA
CUSIP98419J10
Phone510-204-7239

Debt

Debt-to-Equity Ratio2.59
Current Ratio7.26
Quick Ratio7.26

Price-To-Earnings

Trailing P/E Ratio15.95
Forward P/E Ratio-30.42
P/E GrowthN/A

Sales & Book Value

Annual Sales$52.69 million
Price / Sales3.82
Cash Flow$2.0399 per share
Price / Cash11.78
Book Value$0.71 per share
Price / Book33.85

Profitability

EPS (Most Recent Fiscal Year)$0.98
Net Income$14.59 million
Net Margins40.44%
Return on Equity-670.15%
Return on Assets56.39%

Miscellaneous

Employees12
Outstanding Shares8,380,000
Market Cap$209.90

XOMA (NASDAQ:XOMA) Frequently Asked Questions

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

How were XOMA's earnings last quarter?

XOMA Corp (NASDAQ:XOMA) issued its quarterly earnings data on Wednesday, May, 9th. The biotechnology company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.07. The biotechnology company earned $0.46 million during the quarter, compared to analyst estimates of $3.69 million. XOMA had a negative return on equity of 670.15% and a net margin of 40.44%. View XOMA's Earnings History.

When is XOMA's next earnings date?

XOMA is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for XOMA.

What price target have analysts set for XOMA?

3 Wall Street analysts have issued twelve-month target prices for XOMA's stock. Their forecasts range from $33.00 to $49.00. On average, they expect XOMA's stock price to reach $41.00 in the next year. This suggests a possible upside of 70.6% from the stock's current price. View Analyst Ratings for XOMA.

What is the consensus analysts' recommendation for XOMA?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Are investors shorting XOMA?

XOMA saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 905,211 shares, an increase of 73.6% from the June 15th total of 521,409 shares. Based on an average trading volume of 214,835 shares, the days-to-cover ratio is currently 4.2 days. Approximately 11.7% of the company's shares are sold short. View XOMA's Current Options Chain.

Who are some of XOMA's key competitors?

Who are XOMA's key executives?

XOMA's management team includes the folowing people:
  • Mr. James R. Neal, CEO & Director (Age 62)
  • Mr. Thomas M. Burns, Sr. VP of Fin. & CFO (Age 44)
  • Mr. Danny J. Hart Jr., VP & Gen. Counsel (Age 42)
  • Dr. Deepshikha Datta, Chief Bus. Officer
  • Dr. Kirk W. Johnson Ph.D., VP of Devel. (Age 58)

Has XOMA been receiving favorable news coverage?

Media headlines about XOMA stock have trended somewhat positive on Saturday, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. XOMA earned a media sentiment score of 0.08 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.93 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of XOMA?

Shares of XOMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $24.03.

How big of a company is XOMA?

XOMA has a market capitalization of $209.90 million and generates $52.69 million in revenue each year. The biotechnology company earns $14.59 million in net income (profit) each year or $0.98 on an earnings per share basis. XOMA employs 12 workers across the globe.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-204-7239 or via email at [email protected]


MarketBeat Community Rating for XOMA (NASDAQ XOMA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  310 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  578
MarketBeat's community ratings are surveys of what our community members think about XOMA and other stocks. Vote "Outperform" if you believe XOMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XOMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.